# QuantoniumOS: Medical Ethics and Clinical Deployment Policy

**Lead Architect:** Luis M. Minier (Independent, Self-Funded Researcher)  
**Project:** Resonant Fourier Transform (RFT) / φ-basis Computational Stack  
**Intellectual Property:** USPTO Application No. 19/169,399  
**Effective Date:** March 2026  

> **Status: Research Framework.** The RFT is an experimental research project. No component of this technology has been validated for clinical use, cleared by the FDA, or approved by any regulatory authority. This policy establishes requirements that must be met *before* any future medical application — it does not represent current capability.

> This document is a companion to [`GOVERNANCE.md`](./GOVERNANCE.md). In the event of conflict, `GOVERNANCE.md` takes precedence.

---

## I. Medical Mission Statement

The machine-level precision (10⁻¹⁵) of the RFT provides a unique capability for the high-fidelity analysis of biological signals including EEG, ECG, MRI, and neuro-prosthetic interfaces. This policy ensures that the pursuit of scientific fidelity never compromises patient safety, clinical integrity, or data privacy.

The RFT is designed to **augment** the capabilities of licensed medical professionals — not replace them. The human physician, clinician, or researcher retains final authority over all diagnostic and therapeutic decisions made using this technology.

---

## II. Clinical Deployment Protocol (FDA Alignment)

Any entity utilizing the RFT stack for clinical diagnostics or therapeutic hardware must adhere to the following:

### Regulatory Pathway
- Commercial clinical deployment within the United States requires the appropriate **FDA 510(k) clearance** or **De Novo classification** prior to any patient-facing deployment.
- International deployments must satisfy the equivalent national medical device regulatory authority (e.g., CE Marking under EU MDR 2017/745, Health Canada, PMDA Japan).

### Software-as-a-Medical-Device (SaMD) Validation
- SaMD implementations must undergo rigorous validation against the QuantoniumOS 10⁻¹⁵ precision benchmarks to ensure **zero-drift in diagnostic reporting**.
- Validation results must be documented, retained, and made available to the relevant regulatory authority upon request.
- Pre-market validation must include adversarial signal testing to confirm the RFT engine does not produce false-negative or false-positive diagnostic outputs under edge-case biological signal conditions.

### Fast-Track Access
- Qualified medical and non-profit research entities may apply for a **Research-to-Clinical Fast-Track** license.
- Fast-track applicants must demonstrate: (a) IRB approval or equivalent, (b) a named principal investigator, and (c) a patient safety and data privacy plan.

---

## III. Data Privacy and Auditability (HIPAA)

In accordance with HIPAA § 164.530 and applicable international medical data standards (GDPR Article 9 for special category health data):

### Audit Log Retention
- All medical-grade deployments of RFT-native processing logs must be retained for a **minimum of seven (7) years** from the date of last patient interaction.
- Logs must be stored in an encrypted, tamper-evident format with access control auditing enabled.

### Symbolic Transparency
- Clinical AI agents utilizing RFT logic are **forbidden** from operating in "Black Box" mode.
- Diagnostic reasoning chains must be extractable, human-readable, and fully auditable by licensed medical professionals.
- Any model or agent that cannot produce a step-by-step reasoning trace for a clinical output is non-compliant with this policy and may not be deployed in a patient-facing context.

### Patient Consent
- All patient data processed by RFT-powered systems must be collected under explicit, informed consent.
- De-identified datasets used for model training or benchmarking must comply with HIPAA Safe Harbor or Expert Determination de-identification standards.

---

## IV. Social Impact Licensing

Preferential licensing terms are available for:

| Applicant Type | Terms |
|---|---|
| Non-profit medical research organizations | Royalty-free access under CC-BY-NC with attribution |
| Global health initiatives (underserved populations) | Negotiated cost-recovery licensing, no profit extraction |
| Academic medical centers | Standard CC-BY-NC academic tier |
| Public health emergency responders | Emergency fast-track, no upfront fee |

The democratization of high-fidelity diagnostic tools for underserved and under-resourced populations is a **core mandate** of this project, not an optional addendum.

---

## V. Human Medical Professional Primacy

No deployment of any RFT-powered diagnostic or therapeutic system shall:

1. Issue a clinical diagnosis or treatment recommendation without a licensed human medical professional in the review and approval loop.
2. Operate autonomously in a surgical, pharmaceutical dosing, or life-support context without continuous human override capability.
3. Be marketed as a replacement for licensed clinical judgment.

Violation of this section constitutes an automatic breach of the `GOVERNANCE.md` charter and triggers immediate license revocation.

---

## VI. Ethical Review Requirement

All clinical and medical research deployments must receive prior approval from:

- An **Institutional Review Board (IRB)** or equivalent ethics committee, AND
- The QuantoniumOS IP estate (Luis M. Minier or designated trust) for license confirmation

before any patient data is processed or any clinical output is generated.

---

*This policy is effective as of March 2026 and will be reviewed annually or upon any material change to the regulatory landscape.*

**Signed,**  
Luis M. Minier  
Lead Architect & Sole Inventor  
QuantoniumOS / Resonant Fourier Transform  
USPTO Application No. 19/169,399  
March 2026
